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Abstract: Nasopharyngeal carcinoma (NPC) is a polygenetic disease. SPLUNC1, UBAP1, BRD7, NAG7, NOR1, NGX6 
and LTF genes were found to be tumor suppressor/susceptibility genes in different stages of NPC. SPLUNC1, an early 
warning molecular diagnosis marker, inhibits the bacteria clone formation, and is an innated immune molecule. 
SPLUNC1 can negatively regulate the ERK/MAPK signaling transduction pathway to inhibit NPC cell proliferation and 
induce apoptosis. BRD7, a transcript regulation factor, interacts with BRD2, and promotes apoptosis induced by BRD2. 
Its promoter is regulated by c-Myc and SP1. BRD7 inhibits NPC cell cycle progression, preventing passage through 
G0/G1 by suppressing ras/MEK/ERK, Rb/E2F and Wnt signaling pathways. Abnormal activation of BRD7 is crucial to 
cell cycle turbulence in NPC. NGX6, a metastasis-associated protein, can negative-regulate the EGF/Ras/MAPK signaling 
transduction pathway, and interacts with ezrin protein to inhibit NPC cell invasion and metastasis. LTF, also a metastasis-
associated protein, can negatively regulate MAPK signal transduction pathways, such as JNK2 and ERK, to inhibit NPC 
cell proliferation and growth. Taken together, it was found that these tumor suppressor/susceptibility genes can regulate 
key molecules involved in cell signal pathways such as ras/MEK/ERK, Rb/E2F and EGFR ras/MEK/MAPK, and can 
regulate the expression of some adhesion molecules such as ezrin, nm23 and -catenin. According to functional genomics 
and signaling transduction pathways, we have described a signaling cross-talk network between the tumor suppres-
sor/susceptibility genes involved in NPC. These tumor suppressor/susceptibility genes may be potential treatment targets 
for NPC in the future. 
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INTRODUCTION 
  Nasopharyngeal carcinoma (NPC) is a multifactorial dis-
ease that presents a challenge to clinicians and biologists in 
various fields including epidemiology, genetics, virology and 
immunology [1]. NPC has a striking geographical distribu-
tion and Southern China is a major nasopharyngeal carci-
noma-endemic region. Chinese emigrants continue to have a 
high incidence of the disease, but the rate of NPC among 
ethnic Chinese born in North America is considerably lower 
than those born in China [2]. This epidemiologic evidence 
implies that both environmental factors and genetic suscepti-
bility play roles in the development of NPC. The possible 
existence of several susceptibility genes (including two of 
them on the 4q [3] and 3p [4] chromosomes) pointed to the 
importance of epidemiology and genetics in NPC. Cellular 
gene alterations also contribute to NPC development, espe-
cially inactivation of tumor suppressor genes, such as 
SPLUNC1, UBAP1, BRD7, NOR1, NGX6 and LTF, which 
are involved in different stages of NPC initiation and pro-
gression (Fig. 1) [5]. 6 SNP of BRD7 (C450T and A737C), 
NGX6 (rs879284), UBAP1 (rs1049557) and NOR1 
(ss2220003 and ss3211583) have been demonstrated to be 
important genetic susceptibility risk factors for NPC [6-9]. 
Xiao et al. found that the expression of UBAP1 decreases 
during NPC development and progression from normal   
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epithelium of nasopharynx to hyperplastic epithelium of na-
sopharynx, then, to atypical hyperplastic epithelium of the 
nasopharynx and finally, to nasopharygeal carcinoma [5]. 
  Although combination radiotherapy/chemotherapy is 
sensitive for stage I and II NPC and improves survival rates, 
unfortunately the majority of NPC is diagnosed in advanced 
stages because of nonspecific presenting symptoms (cervical 
nodalenlargement, headache, nasal and aural dysfunction), 
delay in seeking treatment after the onset of symptoms, and 
the difficulty of a thorough nasopharyngeal exam [10]. In 
light of this, more precise molecular diagnosis and targeted 
treatments of NPC need to be developed. In this review, the 
function of tumor suppressor/susceptibility genes in different 
stages of NPC and signal transduction mediated by tumor 
suppressor/susceptibility genes will be discussed. Specifi-
cally, we will provide evidence for molecular diagnosis, 
prognosis and targeted treatments in NPC. 
SPLUNC1, AN EARLY WARNING MOLECULAR DI-
AGNOSIS MARKER, IS INVOLVED IN ERK/MAPK 
AND NF-B SIGNALING PATHWAYS, WHICH IN-
DUCE CELL APOPTOSIS IN NPC 
  SPLUNC1 (short palate, lung, and nasal epithelium clone 
1) is isolated from human nasopharyngeal epithelia by sup-
pression subtractive hybridization (SSH) and cDNA microar-
ray analysis [11]. Its expression is downregulated in 70% of 
nasopharyngeal carcinoma (NPC) biopsies but upregulated 
in 25% of lung cancer biopsies. SPLUNC1 is a gene tran-
script of the PLUNC gene family and also is a member of the  
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BPI (bactericidal permeability increasing protein)/LBP 
(lipopolysaccharide-binding protein) family with putative 
bactericidal/bacteriostatic functions. All BPI and LBP, in-
cluding SPLUNC1 are bactericidal proteins and have the 
function of neutralizing endotoxin [12-14]. SPLUNC1 is 
downregulated in slight atypical hyperplasia of nasopharynx 
endepidermis, and its expression gradually decreases with 
progression of malignant nasopharynx endepidermis from 
slight atypical hyperplasia to nasopharyngeal carcinoma 
[15]. It is found to scavenge bacterial endotoxin [16], EB 
virus [16] and it also can combine with nanobacteria [17] 
and ameliorate its deleterious effects. Furthermore, it is in-
volved in the earliest stage of NPC carcinogensis, where it 
plays a role in innate immunity. Thus, SPLUNC1 is an early 
warning molecular diagnosis marker and is used to carry out 
early diagnosis and crowd risk forecasting for NPC.  
  The MAPK (mitogen-activated protein kinase) cascade 
relays the presence of extracellular stimuli such as growth 
hormones to the nucleus and controls the expression of hun-
dreds of genes. MAPKs control major cell fate decisions 
such as proliferation, differentiation and apoptosis, mainly 
by inducing alterations in gene expression [18]. The MAPK 
cascade includes four main signaling pathways, ERK, JNK, 
P38 and ERK5. SPLUNC1 enhances apoptosis of NPC 
HNE1 cells and EBV-transformed human B-lymphocytes 
[16]. SPLUNC1 evidently inhibits the expression of phos-
phorylated ERK (p-Tyr-204) and its BPI domain contributes 
to this inhibitory effect. SPLUNC1 inhibits the expression 
JNK2, not JNK1, and has no effect on total P38 protien or 
phosphorylated P38 (p-Tyr-182). At the same time, 
SPLUNC1 can promote expression of NF-B (Nuclear factor 
NF-B) and I- protein, which is an inhibitory effect de-
pendent upon its BPI domain, but the inhibitory effect of 
phosphorylated I-(p-Ser-32) has nothing to do with its BPI 
domain. Therefore, SPLUNC1 can regulate ERK/MAPK and 
NF- kB signaling pathways to induce cell apoptosis in NPC 
[15]. 
DOWNREGULATED EXPRESSION OF RASSF1A IS 
INVOLVED IN NF-B SIGNALING PATHWAY  
  Ras-association domain family of proteins (RASSF) are 
characterized by the Ras-association (RA) domain at the C-
terminal. RASSF1A is a target tumor suppressor gene on 
3p21.3 in NPC. The aberrant hypermethylation of RASSF1A 
and high EBV load might be important events in NPC 
pathogenesis and they may be useful molecular diagnostic 
markers for this cancer [19-21].  Downregulation of 
RASSF1A expression is dependent on the activation of in-
tracellular signaling of NF-B involving the C-terminal acti-
vating regions (CTARs) of LMP1 [22]. 
BRD7, A NUCLEAR TRANSCRIPTION FACTOR, 
REGULATES CELL CYCLE PROGRESSION BY 
MEK/ERK/MAPK, Rb/E2F AND Wnt/-CATENIN 
PATHWAYS 
  Cell cycle progression is a strictly controlled process and 
it needs precise interplay between many molecules. The 
regulatory pathway controlling G1–S is the Rb/E2F path-
way: in the presence of extracellular growth-stimulatory sig-
nals, cyclinD1 and its kinase partner cdk4 form an activated 
complex and phosphorylate Rb and Rb family members, thus 
inactivating Rb and allowing E2F/DP transcription factors to 
exert their transactivation activity. This in turn leads to tran-
scription of a number of genes essential for DNA replication 
and entry into S phase, thus the cell enters into S phase and 
completes the irreversible cell cycle progression [23]. BRD7 
is a nuclear transcription regulation factor containing a bro-
modomain that is found in many chromatin-associated pro-
teins and in nearly all known nuclear histone acetyltrans-
ferases (HATs) and has been found to play an important role 
in chromatin remodeling and transcriptional activation [24]. 
The transcriptional regulation of BRD7 is achieved by bind-
ing to acetylated histone H3 at Lys14. The bromodomain is 
essential for this role. Chromatin remodeling, not chromatin 
modiﬁcation, is the major mechanism of BRD7 mediated 
gene transcription [25]. The downexpression of the BRD7 
gene has been shown to be critical to the pathogenesis of 
NPC [26]. Promoter methylation inhibits BRD7 expression 
in NPC [27] and its promoter is regulated by c-Myc and Sp1 
[28]. BRD7 interacts with BRD2 and stimulates apoptosis 
induced by BRD2. BRD7 protein inhibited cell growth and 
cell cycle progression from G1 to S phase by transcription-
ally regulating some cell cycle associated genes such as Rb 
and E2F3 in NPC cells [29]. Zhou et al. [29] and Peng et al. 
[30] found that potential targets of BRD7 were mainly in-
volved in MEK/ERK/MAPK, Rb/E2F and Wnt/-catenin 
signaling pathway.  
  Extra-cellular signals can be transmitted into the nucleus 
cell cycle machinery through diverse signaling pathways, 
among which MEK/ERK/MAPK is one intensively studied 
pathways [31]. The over-expression of BRD7 in NPC cells 
results in the downregulation of the c-jun, p-MEK and p-
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ERK1/2 expression and Ap-1 promoter inactivity, therefore, 
BRD7 plays a negative role in the MEK/ERK/MAPK path-
way [29]. E2Fs and DPs protein are both transcription factor 
families that can form heterodimers that play central roles in 
the expression of genes essential for S phase entry [23]. The 
expression of DP2 and E2F3 were both decreased by the 
induction of BRD7, peaking 4.0- and 6.0-fold, respectively 
[29] and the transcription targets of E2F/DP, such us replica-
tion factor A (RFA), replication factor C37 and 38 subunit 
(RFC37 and RFC38), were all downregulated as a result of 
the decrease of E2F3/DP2. RFA and RFC are important 
components for DNA replication initiation by contributing to 
origin unwinding, primering and ﬁring during DNA replica-
tion [32]. BRD7 interacts with Ceap-16 (centrosome associ-
ated protein-16, also termed BLOS2) by C-terminus of 
BRD7 and the central region of Ceap-16. Through this bind-
ing, Ceap-16 can translocate from cytoplasm to the nucleus 
where it selectively inhibits the transcriptional suppression 
activity of BRD7 towards certain target genes including 
E2F3 and cyclin A [33]. In addition, Kim et al. [34] reported 
that BP75, the most homologous gene of BRD7 (bromodo-
main containing protein 7), was found to bind dishevelled-1 
and enhance Wnt signaling by inactivating GSK-3 (glyco-
gen synthase kinase-3 beta). In NPC cells, the induction of 
BRD7 increased the expression of -catenin which “hold” 
-catenin in the complex and inhibit -catenin accumulation 
in the nucleus to induce the downregulation of cyclinD1, 
E2F3 [30]. As a nuclear transcription regulation factor, the 
nuclear localization of BRD7 is critical for the expression of 
cell cycle related molecules and cell biological function. 
NLS (nuclear localization signal) is an essential motif affect-
ing BRD7 nuclear distribution, and NLS-deleted BRD7 
shifts the nuclear localization mostly to the cytoplasm, and 
failed or reduced to negatively regulate the expression of cell 
cycle related molecules, cyclin D1 and E2F3, and cell cycle 
progression from G1 to S phase [35].  
NGX6, A METASTASIS-ASSOCIATED PROTEIN, 
CAN NEGATIVE-REGULATED EGF/Ras/MAPK 
SIGNALING PATHWAY AND INTERACT WITH 
EZRIN PROTEIN TO INHIBIT INVASION AND ME-
TASTASIS OF NPC CELLS
  Cancer metastasis is a very complicated biological proc-
ess involving many sequential steps. Cell-cell and cell-
extracellular matrix (fibronectin, laminin, collagen, etc.) in-
teractions are involved in the metastatic process [36]. NGX6 
(nasopharyngeal carcinoma (NPC)-associated gene 6) is a 
metastasis-associated gene located on human chromosome 
9p21–22. Loss of NGX6 expression is associated with lymph 
node or distance metastasis in colorectal carcinomas [37] and 
NPC [38]. The NGX6 protein includes two transmembrane 
(TM) regions. The extracellular region contains one epider-
mal growth factor (EGF)-like domain and three potential N-
glycosylation sites, and the short cytoplasm (CYTO) con-
tains a tyrosine residue that is a potential tyrosine kinase-
phosphorylation site. The EGF-like domain is a sequence of 
40 aa residues long, which has a significant homology to 
EGF. The EGF-like domain, which contains a unanimous 
sequence of CX7CX 2–3GXCX10–13 CXCX3YXGXRCX 
5–n, is involved in the interaction between receptors and 
ligands in cell adhesion and signal transduction [39]. Mole-
cules containing EGF-like domains are mostly involved in 
cell adhesion, matrix formation, injury, recovery and chemo-
taxis [39]. N-Glycosylation sites are signatures of some cell 
adhesion molecules [38]. NGX6 modulates the adhesion and 
invasion process via  both the EGF-like domain and the 
CYTO region [40], and could delay cell cycle G0-G1 pro-
gression and thus inhibit cell proliferation by negatively 
regulating the EGFR Ras/Mek/MAPK pathway in NPC cells. 
As an EGF-like domain gene [41], NGX6 influences the 
expression of some important cell adhesion-related mole-
cules. In NPC cells, the expression of RhoA and vitronectin 
are both decreased following the induction of NGX6, and the 
induction of NGX6 up-regulates the expression of KRT1, 
integrin a2, integrin b7, PSCD2L, CD9, ezrin, nm23-H1, 
VE-cadherin and catenin a2. RhoA is implicated in the inva-
sion of human microvascular endothelial cells (HMEC-1). 
Ectopic expression of active-RhoA GTPase induces the ex-
pression of the MMP-9 metalloproteinase [38]. Vitronectin 
can promote cell adhesion and spreading. In normal tissue, 
vitronectin has a homogeneous periductal occurrence, with 
local accumulations much lower than in carcinoma tissues 
[38]. KRT1 is a member of the keratin gene family associ-
ated with differentiation [38]. Integrins are a family of 
transmembrane glycoproteins that participate in a wide range 
of cellular events including cell adhesion, proliferation, 
apoptosis, differentiation and cell-surface-mediated signaling 
[38]. PSCD2L (Cytohesin-1) can specifically interact with 
CD18 (integrin b2) and can promote cell adhesion to ICAM1 
[38]. CD9 is a cell-surface glycoprotein, that can modulate 
cell adhesion and migration and that can also trigger platelet 
activation and aggregation [38]. Nm23-H1 is a tumor metas-
tasis inhibitor in many tumors [38]. VE-cadherin is a cal-
cium-dependent cell--cell adhesion glycoprotein [38]. The up 
or down-regulation of those adhesion molecules reflects a 
possible role of NGX6 in tumor invasion and metastasis.  
  Ezrin has been suggested to be a mediator of cell motil-
ity, is essential for the maintenance of cell-cell adhesion, and 
is inhibitory towards cell matrix adhesion in human colonic 
epithelial cells. Ezrin, a linker between membrane protein 
and cytoskeleton, plays an important role in cell morphol-
ogy, cytoskeleton reorganization, adhesion, invasion and 
metastasis. NGX6 can interact with ezrin via its cytoplasmic 
region [38, 42]. NGX6 and ezrin expression is negatively 
correlation in tissue from NPC biopsies, and the positive 
ratio of ezrin expression may be associated with the clinico-
pathological phase [42]. Ezrin is an important promoting 
factor in the development and metastasis of NPC. The posi-
tive expression ratio of ezrin in NPC patients is greater than 
that in non-NPC patients, and the positive ratio of ezrin in 
NPC patients with lymph nodes metastasis was much greater 
than that in NPC patients without metastasis. Ezrin can also 
bind to cell adhesion molecules such as CD44, CD43, CD46, 
ICAM-1, ICAM-2 and ICAM-3, and be coprecipitated with 
E-cadhein and -catenin, all of which are implicated in cell 
migration and metastasis [43]. The interaction of NGX6 with 
ezrin suggests that NGX6 participates in cell migration and 
metastasis modulation. NGX6 plays an inhibitory role in the 
migration and invasion of NPC cells by interacting with 
ezrin and down-regulating the expression of ezrin and ezrin-
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NAG7, AN ESTROGEN RECEPTOR REPRESSOR, 
STIMULATES THE INVASIVE POTENTIAL OF HU-
MAN NPC CELLS BY REGULATING OF ER EX-
PRESSION AND THE H-ras/p-c-RAF AND JNK/AP-
1/MMP1 SIGNALING PATHWAYS 
  NAG7 (NPC-associated gene-7) located on 3p25.3, also 
known as ERR-10 (estrogen receptor repressor-10), is down-
regulated in many NPC biopsy samples and in the NPC cell 
line HNE1 [44]. As an estrogen receptor repressor, NAG7 
can interact with the estrogen receptor  (ER), and reduce 
17-estradiol (E2) induced activation of ER transcriptional 
activity in transient transfection assays of mammalian cells 
[45]. ER is a nuclear transcription factor that regulates gene 
expression by binding to specific estrogen-responsive ele-
ments (ERE) on target gene promoters. ER promotes breast 
cancer cell growth, but paradoxically, it also inhibits cancer 
cell invasion in vitro and metastasis in vivo [46-49]. ER 
plays opposing roles in promoting cancer cell growth and 
inhibiting its invasion and metastasis. NAG7 is a negative 
regulator of ER, and has a double effect on proliferation and 
invasion of NPC cell lines. In NPC HNE1 cells, overexpres-
sion of NAG7 inhibits the proliferation by arresting cell cy-
cle progression from G1 to S phase and inducing apoptosis 
[50-52]; but it increases the adhesion, motility and invasion 
of cells, both in vitro and in vivo, by down-regulating ER 
expression in a E2-independent manner. NAG7 suppresses 
ER expression and stimulates cell invasion via the H-ras/p-c-
Raf and JNK/AP-1/MMP1 pathways [53]. The Ras proto-
oncogene, a small GTP/GDP-binding protein, is a central 
component of mitogenic signaling and is a critical player in 
cancer progression. It affects the progression of human ma-
lignancies by increasing proliferation, enhancing invasion 
and altering cytoskeletal organization [54]. Activation of a 
linear pathway Ras–Raf–MAPK kinase (MEK) results in 
phosphorylation and activation of MAPK [55]. NAG7 over-
expression in HNE1 cells increases the expression of H-Ras, 
which leads to the activation of p-c-Raf, while the expression 
of K-Ras, N-Ras and total c-Raf is unchanged [53]. NAG7 
gene influences the H-ras/p-c-Raf pathway, leading to 
MAPK signal activation. MAPKs consist of ERK, c-Jun 
NH2-terminal kinase (JNK), and p38 cascades. JNK activity 
is essential for cancer proliferation, transformation, invasion 
and metastasis. Moreover, a positive correlation exists be-
tween JNK and lymph node metastases in breast cancer pa-
tients [56-58]. It has been reported that JNK may induce 
changes in the expression of c-Jun in hepatocellular carci-
noma cells, resulting in increased expression and enzymatic 
activity of MMP1 [59]. Degradation of collagen is one of the 
most critical steps in the invasive and metastatic processes of 
cancer progression, and up-regulation of MMP-1 is associ-
ated with increased cellular invasion and poor prognosis in 
patients with colorectal, esophageal and advanced gastric 
cancers [60, 61]. MMP-1 may also promote cell adhesion 
and motility by influencing cytoskeletal arrangements 
through its association with different cell adhesion molecules 
such as CD44 and integrins [61]. NAG7 significantly in-
creases the expression of JNK2 and c-Jun and down-
regulated c-Fos, while leaving ERK and p38 unaffected. It 
also causes an increase in the transcriptional activation of 
AP-1, which up-regulates the production of MMP-1 [53]. E2 
has been reported to up-regulate MAPK phosphatases in 
breast cancer cells [62], but NAG7 stimulates the JNK2/AP-
1/MMP1 pathway in an E2-independent manner. This sug-
gests that NPC tumorigenesis does not involve estrogen 
stimulation [53]. 
LTF, A METASTASIS-ASSOCIATED PROTEIN, CAN 
NEGATIVE-REGULATE THE MAPK SIGNALING 
TRANSDUCTION PATHWAY 
 LTFLactotransferrinalso referred to as lactoferrin, LF) 
is a secreted iron-binding glycoprotein that defends against 
microbial pathogens in innate immunity [63]. Recently, LTF 
has been found to have antitumor activity thus regulating 
tumorigenesis [64-66]. LTF is identified from NPC suscepti-
bility locus in chromosome 3p21.31-21.2, which is a site of 
frequent loss of heterozygosity in NPC [67, 68]. The expres-
sion of LTF is downregulated in NPC biopsy samples [68], 
and is negatively associated with the progression and metas-
tasis of NPC. LTF is expressed at a significantly lower fre-
quency at the T3/T4 stage or in NPCs with local lymph node 
metastasis compared to that of NPC at early stages or with-
out metastasis [67]. LTF may act as a tumor suppressor, 
downregulating the progression and metastasis of NPC. In-
duction of LTF gene expression in NPC or modulation of 
cyclin D1, p21 and p27 expression, as well as Rb phosphory-
lation and signaling through the MAPK pathway may inhibit 
the development and progression of human NPC [67]. LTF 
treatment inhibits cyclin D1 expression and Rb phosphoryla-
tion, and increases levels of p21 and p27 expression. 
Upregulation of p21 and p27 may downregulate the expres-
sion of cyclin D1 and Rb phosphorylation contributing to 
NPC growth inhibition [67]. LTF treatment for 12 or 24 hr 
dramatically reduces expression levels of JNK2 and c-Jun in 
addition to ERK1/2 phosporylation or c-fos expression, re-
spectively. Extending treatment for longer periods resulted in 
a continued decrease in the levels of p-ERK1/2 and c-fos 
expression in 5–8F NPC cells in vitro. However, LTF treat-
ment does not modulate expression levels of total ERK1/2, 
STAT3 and p53 and STAT3 phosphorylation [67]. Inhibition 
of NPC cell proliferation by LTF is partially mediated 
through modulation of the MAPK signal transduction path-
way, but is independent of p53 and STAT3 signaling. 
THE INCREASED ACTIVITY OF p16 AND p27 BY 
SUPPRESSOR/SUSCEPTIBILITY GENES IS RE-
LATED TO MULTIPLE SIGNALING CASCADES 
  Both p16 and p27 are cyclin-dependent kinase inhibitory 
proteins (CKI) that suppress activity and are frequently inac-
tivated in NPC. p16 negatively regulates cyclin D1 activity 
to suppress CDK4, subsequently to control the G1/S check-
point; and phosphorylated p27 allows the cdk2/cyclin E 
complex to remain activated allowing for cell cycle progres-
sion [10]. A majority of NPCs exhibit low level expression 
of p16 and p27 in dysplasia epithelium of nasopharynx. Sup-
pressor/susceptibility genes increase activity of p16 and p27 
by suppressing multi-signaling cascades, such as ERK/ 
MAPK, JNK/c-Jun, Rb/E2F.  
  In conclusion, the development and progression of NPC 
involves in the alteration in expression of numerous onco-
genes or tumor suppressor/susceptibility genes and the aber-
rations of a large variety of signaling pathways. According to 220    Current Genomics, 2009, Vol. 10, No. 4  Wu et al. 
functional genomics and signaling transduction pathways, 
we have described a signaling cross-talk network between 
the tumor suppressor/susceptibility genes involved in NPC 
(Fig. 2). These tumor suppressor/susceptibility genes may be 
potential treatment targets for NPC in the future. 
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